Navigation Links
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Date:10/25/2007

DEERFIELD, Ill., Oct. 25 /PRNewswire/ -- Astellas Pharma US, Inc. today announced data demonstrating that VAPRISOL(R) (conivaptan hydrochloride injection) effectively raises serum sodium concentration ([Na+]) and is well-tolerated among hospitalized patients with euvolemic or hypervolemic hyponatremia, a potentially life-threatening condition that occurs when the body's sodium level falls below normal. The efficacy and safety profile of VAPRISOL was comparable under double-blind or open-label conditions. The study results were presented at the American College of Chest Physicians (CHEST) 2007 meeting.

"Hyponatremia is common in patients with congestive heart failure and in patients with the syndrome of inappropriate antidiuretic hormone (SIADH), which is seen in various pulmonary disorders and postsurgical settings," said Joseph G. Verbalis, M.D., at the Georgetown University Hospital. "These data suggest that VAPRISOL can safely and effectively raise serum sodium levels in patients with underlying conditions such as pneumonia, chronic obstructive pulmonary disease and impaired heart function."

VAPRISOL is the first in a new class of arginine vasopressin (AVP) receptor antagonists. VAPRISOL blocks both V1a and V2 vasopressin receptors, resulting in increased urine output without increased sodium loss. This effect, known as "aquaresis," increases serum sodium levels and helps to restore salt and water balance in patients with hyponatremia due to increased body water (dilutional hyponatremia).

VAPRISOL is approved by the U.S. Food and Drug Administration as a treatment for euvolemic and hypervolemic hyponatremia in hospitalized patients. VAPRISOL is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. The approved doses for VAPRISOL include 2
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- Aspire Technology Partners (Aspire) announced today that it has ... designation recognizes Aspire for delivering outstanding customer service to customers ... "Achieving exceptional results for our customers is core ... and CEO of Aspire. "We are pleased Cisco has recognized ... and are proud to be part of the Cisco channel." ...
(Date:8/1/2014)... , Aug. 1, 2014 ... of the "Global Medical Biosensors Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Medical biosensors ... help of physicochemical detectors. These biosensors monitor health ... invasive and non-invasive methods. They are cost-effective and ...
(Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3
... NEW YORK, June 13, 2011 Reportlinker.com ... is available in its catalogue: ... in Key SADC Countries ... aim of this research service is to ...
... 2011 Science, public health, and regulatory highlights from ... this document is designed for credentialed journalists. Release dates and ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... or enforcement actions due to legal limitations. ...
Cached Medicine Technology:Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
(Date:8/1/2014)... Oxford Gene Technology (OGT) is a ... include CytoSure heamatological cancer +SNP Array, CytoSure ISCA ... array, CytoSure ISCA sample tracking spike-ins and CytoSure ... as targeted sequencing services, SureSeq Solid Tumour Panel ... analysis, cytosure services and aCGH for CNV analysis. ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Roaming the ... preserved mummy became famous as the "Ice Man" no doubt ... of that may still not have shielded the Ice Man, ... A human,s genetic risk for atherosclerosis, or "hardening of the ... thousands of years ago, a new study finds. ...
(Date:8/1/2014)... LA The Health Resources and Services Administration ... Orleans School of Nursing an Advanced Nursing Education ... years. The funding will support training interprofessional teams ... for military veterans and diverse populations with behavioral ... DNP, CRNA, LSUHSC Nurse Anesthesia Program Director and ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... "Des" O,Neill, MA, MD, FRCPI, AGSF, FRCP(Glasg), FRCP, FRCP(Edin), ... the 2014 recipient of the Joseph T. Freeman Award. ... geriatrics and is awarded to a prominent physician in ... practice who is a member of the Society,s ...
(Date:8/1/2014)... 01, 2014 Lifeinsurancenomedicalexam.info has released ... insurance for clients who have high cholesterol levels. ... find and qualify for no medical exam life insurance. ... any background medical check-ups. , Since there are no ... level will qualify in just a few minutes. However, ...
Breaking Medicine News(10 mins):Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2Health News:LSUHSC Nursing awarded $1 million grant to improve care for veterans 2Health News:O'Neill to receive GSA's 2014 Joseph T. Freeman Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2
... in French . A team of ... have discovered a type of "cellular bilingualism" a ... different methods of communication to exchange information. "Our work ... function of dopaminergic, serotonergic and cholinergic neurons in diseases ...
... By Alan Mozes HealthDay Reporter , THURSDAY, March ... therapy may have gotten a little closer to reality, with ... hearts that were dangerously swollen after heart attacks. The ... bone marrow, then injecting them into the patient,s damaged heart. ...
... , WEDNESDAY, March 16 (HealthDay News) -- ... children participating in their school,s band, a new study ... high school band and found they were heavily contaminated ... which are associated with minor to serious infections and ...
... for the first time that stem cells injected into ... improved function to injured heart areas, according to a ... the American Heart Association . , Researchers said that ... findings are promising for the more than five million ...
... increasing frequency, parents of children with autism spectrum disorder ... their children wander or unexpectedly run away. One mother ... wandered away from her home, despite efforts to lock ... this problem, Autism Speaks, the world,s largest autism science ...
... -- Many American children who qualify for public health ... parents are confused about enrollment and eligibility, new research ... low-income households in Oregon and found that about 23 ... were not enrolled in the Oregon Health Plan (OHP), ...
Cached Medicine News:Health News:'Bilingual' neurons may reveal the secrets of brain disease 2Health News:Stem Cell Therapy Shrinks Enlarged Hearts 2Health News:Stem Cell Therapy Shrinks Enlarged Hearts 3Health News:Heart damage improves, reverses after stem cell injections in a preliminary human trial 2Health News:Autism Speaks supports new diagnostic code for individuals with autism with history of wandering 2Health News:Parents Often Confused About Kids' Health Coverage 2
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Medium. 22.50 mm by 24.00 mm. Clear lucite. Supplied sterile....
... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: